苏州轴承厂股份有限公司 投资者关系活动记录表 证券代码：920418 证券简称：苏轴股份 公告编号：2025-113 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律 责任。 一、 投资者关系活动类别 □特定对象调研 √业绩说明会 □媒体采访 □现场参观 □新闻发布会 □分析师会议 □路演活动 □其他 二、 投资者关系活动情况 活动时间：2025 年 11 月 12 日 活动地点：价值在线（https://www.ir-online.cn/） 参会单位及人员：线上参与公司 2025 年第三季度报告业绩说明会的全体投资者 上市公司接待人员：公司董事、董事长：张文华先生；公司董事、总经理：彭君雄 先生；公司董事会秘书：沈莺女士；公司财务负责人：鲁斌先生。 三、 投资者关系活动主要内容 本次业绩说明会通过视频解读等形式对公司情况及 2025 年第三季度经营业绩情况 进行了介绍。同时公司就投资者关心的问题进行了沟通交流，主要问题及回复如下： 问题 1：公司在机器人和航空航天等高端制造取得了哪些成绩？ 1 / 3 回复：尊 ...

Investment Rating - The report assigns an "Accumulate" rating for the company, indicating a positive outlook on its development in the robotics sector [1]. Core Views - The company achieved operating revenue of 538 million yuan in the first three quarters of 2025, a year-on-year decrease of 1.7%, while the net profit attributable to shareholders was 118 million yuan, a year-on-year increase of 0.7% [1][6]. - The company's products have gained recognition from both domestic and international clients, establishing itself as a leading manufacturer in the needle bearing industry, with partnerships with notable companies such as Bosch and ZF [6]. - The investment suggestion anticipates earnings per share of 1.01 yuan and 1.14 yuan for 2025 and 2026, respectively, with corresponding price-to-earnings ratios of 30 and 26 [6][7]. Financial Performance Summary - For the first three quarters of 2025, the company's gross profit margin was 36.79%, a decrease of 1.75 percentage points compared to the same period last year [6]. - The company reported a decline in quarterly revenue for Q3 2025, with a revenue of 180 million yuan, down 4.32% year-on-year and 3.23% quarter-on-quarter, and a net profit of 36 million yuan, down 17.75% year-on-year and 25.00% quarter-on-quarter [6]. - The company maintained good cost control, with total expense ratios decreasing to 6.47%, a year-on-year decrease of 1.40 percentage points [6].

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别 及连带法律责任。 一、 投资者关系活动类别 □特定对象调研 证券代码：920418 证券简称：苏轴股份 公告编号：2025-112 苏州轴承厂股份有限公司 投资者关系活动记录表 □业绩说明会 □媒体采访 活动地点：上海丽思卡尔顿酒店 参会单位及人员：上海岱熹投资管理有限公司、万柏私募基金管理有限公司、东海 基金管理有限责任公司、开源证券股份有限公司、上海贝寅私募基金管理有限公司、财 信证券股份有限公司、国泰海通证券股份有限公司、旦恩资本管理有限公司 □现场参观 □新闻发布会 □分析师会议 □路演活动 √其他 （线下会议） 二、 投资者关系活动情况 活动时间：2025 年 11 月 5 日 上市公司接待人员：董事会秘书沈莺女士，财务负责人鲁斌先生 问题 4：公司的海外客户是否有海外建厂要求？ 回答：海外客户提出过相关要求，公司对于海外建厂需求将进行积极研究，视 公司具体发展情况而定。 问题 5：公司产品海外市场占比情况？ 问题 1：客户价格调整对公司后期经营的影响多大？ 回答 ...

Group 1 - The event "Investor Zero Distance" focused on the company Deyuan Pharmaceutical, part of the North Exchange 50 index, highlighting its innovative growth in the pharmaceutical industry [2][7] - Over 40 institutional representatives and investors participated in the event, engaging with company executives to understand the company's operations and market potential [2][6] - Deyuan Pharmaceutical specializes in the research, production, and sales of chronic disease treatment drugs, particularly in the endocrine therapy sector, and is expanding its product pipeline in related fields [4][6] Group 2 - The company's chairman and board secretary provided insights into the current business operations, strategic direction, and core technologies during face-to-face discussions with investors [6] - Industry experts discussed the North Exchange market, the North Exchange 50 index fund, and the long-term investment value of the A-share pharmaceutical sector during a subsequent seminar [6] - The event aimed to enhance communication between investors and listed companies, fostering a better understanding of company fundamentals and promoting rational investment culture [7]

Investment Rating - The investment rating for the company is "Outperform" (maintained) [3] Core Views - The company is actively advancing its smart transformation and digitalization, with a projected net profit growth of 0.70% year-on-year for the first three quarters of 2025 [5] - The company is expanding into high-value new sectors such as aerospace, industrial automation, and high-end equipment, which are expected to drive future growth [6] - The automotive bearing market is anticipated to grow significantly, supported by government policies promoting automotive consumption and upgrades [5] Financial Performance Summary - For the first three quarters of 2025, the company achieved revenue of 538 million yuan, a decrease of 1.70% year-on-year, while the net profit attributable to the parent company was 118 million yuan, an increase of 0.70% [5] - The company maintains its profit forecast for 2025-2027, expecting net profits of 171 million yuan, 201 million yuan, and 225 million yuan respectively [5] - Earnings per share (EPS) are projected to be 1.05 yuan, 1.24 yuan, and 1.38 yuan for 2025, 2026, and 2027 respectively, with corresponding price-to-earnings (P/E) ratios of 29.6, 25.2, and 22.5 [5][7] Industry Insights - The domestic robot production and sales are steadily increasing, with significant growth in industrial robots, which is expected to open new growth opportunities for the company [6] - The automotive industry in China saw a substantial increase in production and sales, with year-on-year growth of 13.3% and 12.9% respectively for the first nine months of 2025 [5] - The automotive bearing market size exceeded 200 billion yuan in the first half of 2025, accounting for over 40% of the total bearing industry size [5]

Group 1 - The event "Investor Zero Distance" focused on Suzhou Z轴股份, a constituent of the North Exchange 50 Index, highlighting its role in supporting innovative small and medium enterprises [1][9] - The event included a site visit and a seminar, allowing over 40 institutional representatives and investors to engage directly with the company's management [1][8] - Discussions centered on the achievements of the North Exchange in serving innovative SMEs, market outlook, and long-term investment value [1][8] Group 2 - Suzhou Z轴股份 has over 60 years of experience in the needle bearing and rolling body industry, with products used in various critical automotive systems and other sectors such as industrial automation and aerospace [4] - The company showcased its production lines and technological capabilities during the investor visit, providing insights into its operational efficiency and R&D strength [4][8] - The chairman and board secretary of Suzhou Z轴股份 engaged in face-to-face discussions with investors about the company's development history, operational status, strategic planning, and core technologies [8] Group 3 - The North Exchange's specialized small giant enterprises, like Suzhou Z轴股份, demonstrate significant innovation and growth potential in the needle bearing industry [8] - The event is part of a series aimed at enhancing communication between investors and North Exchange-listed companies, fostering a better understanding of company fundamentals [9]

证券代码：920418 证券简称：苏轴股份 公告编号：2025-110 苏州轴承厂股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别 及连带法律责任。 一、 投资者关系活动类别 □特定对象调研 □业绩说明会 □媒体采访 活动时间：2025 年 10 月 30 日 活动地点：苏州高新区鹿山路 35 号和苏州高新区珠江路 508-3 号苏州轴承厂股份 有限公司厂区 参会单位及人员：东吴证券股份有限公司、山西证券股份有限公司、东北证券股份 有限公司、长江证券股份有限公司、财通证券股份有限公司、浙商证券股份有限公司、 证券时报、上海证券报、汇添富基金管理股份有限公司、上海百济投资管理有限公司、 盈科创新资产管理有限公司、江苏高科技投资集团、上海贝寅私募基金管理有限公司、 苏州高新创业投资集团太湖金谷资本管理有限公司、苏州高新创业投资集团中小企业发 展管理有限公司、交通银行山西分行、交通银行河南分行、交通银行山东分行、交通银 行浙江分行、交通银行河北分行、交通银行湖南分行、交通银行福建分行 1 / ...

证券代码：920418 证券简称：苏轴股份 公告编号：2025-111 苏州轴承厂股份有限公司 2025 年第三季度报告业绩说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律 责任。 一、 说明会类型 苏州轴承厂股份有限公司（以下简称公司）于 2025 年 10 月 29 日在北京证券交 易所官方信息披露平台（http://www.bse.cn/）披露了《苏州轴承厂股份有限公司 2025 年第三季度报告》（公告编号：2025-107）,为方便广大投资者更深入了解公司 2025 年第三季度经营业绩的具体情况，进一步加强与投资者的互动交流，公司拟召开 2025 年第三季度报告网上业绩说明会。 二、 说明会召开的时间、地点 （一）会议召开时间：2025 年 11 月 12 日（星期三）15:00-16:30。 四、 投资者参加方式 本次说明会采用网络方式召开。 投资者可于 2025 年 11 月 12 日（星期三） 15:00-16:30 通过网址 https://eseb.cn/1sOAHPafFZe ...

Core Insights - The Beijing Stock Exchange (BSE) has released its first evaluation results for listed companies' information disclosure, with an overall excellence rate of 86.2% [1][2] - Among the 262 companies evaluated, 48 received an A rating (excellent), with nearly 80% of companies gaining points for positive actions such as cash dividends and share buybacks [1][2] - The evaluation results may influence companies' refinancing and merger activities, establishing a strong market incentive and constraint mechanism [1][4] Evaluation Results - A total of 262 companies were evaluated, resulting in 48 A-rated (18.3%), 178 B-rated (67.9%), 31 C-rated (11.8%), and 5 D-rated (1.9%) companies [2][3] - Notable A-rated companies include Jinbo Biological, Wuxin Tunnel Equipment, and Airo Technology, while D-rated companies include Tianye Co., Bio Valley, and *ST Yun Chuang [2][3] Improvement in Disclosure Quality - The evaluation indicates that listed companies have made significant progress in enhancing the effectiveness of information disclosure and investor relations management [3][5] - Nearly 80% of companies implemented cash dividends or share buybacks, over 50% engaged with research institutions, and 38 companies proactively disclosed ESG or social responsibility reports [3][5] Regulatory Implications - The evaluation results will be linked to companies' refinancing and merger activities, with A-rated companies receiving support and facilitation from the BSE [4][5] - D-rated companies will face increased scrutiny and guidance, including enhanced disclosure reviews and compliance training for key personnel [4][5] Industry Impact - The release of these evaluation results aligns with similar mechanisms from other major exchanges, marking the establishment of a unified regulatory framework for information disclosure across A-share markets [5] - The shift from "post-event accountability" to "full-process supervision" aims to create a transmission mechanism linking disclosure quality, market reputation, and capital costs, compelling companies to strengthen internal controls and governance [5]

Core Viewpoint - The Beijing Stock Exchange (BSE) has released its first evaluation results for listed companies' information disclosure, showing an overall excellent rate of 86.2%, indicating a strong commitment to transparency and investor relations [1][2]. Group 1: Evaluation Results - Out of 262 companies evaluated, 48 received an A rating (excellent), accounting for 18.3% of the total [2]. - The majority of companies, nearly 80%, received additional points for actions such as cash dividends and share buybacks [1][3]. - The breakdown of ratings includes 178 companies rated B (good) at 67.9%, 31 rated C (qualified) at 11.8%, and 5 rated D (unqualified) at 1.9% [2]. Group 2: Impact on Corporate Behavior - The evaluation results are expected to influence companies' capital operations, including refinancing and mergers and acquisitions [4]. - Companies rated A will receive support and facilitation for their restructuring and issuance activities, including reduced inquiry rounds and targeted training [4]. - Companies rated D will face increased scrutiny and guidance, including enhanced disclosure reviews and compliance training for key personnel [4]. Group 3: Industry Implications - The release of these evaluation results aligns with the regulatory frameworks of other major exchanges in China, marking a shift towards a more unified and proactive regulatory approach [5]. - The evaluation mechanism aims to establish a transmission mechanism linking disclosure quality, market reputation, and capital costs, thereby encouraging companies to strengthen internal controls and governance [5]. - The BSE emphasizes that the evaluation results will motivate companies to improve their operational standards and governance, ultimately protecting the rights of small and medium investors [6].